GKOS

Glaukos Corporation

Fundamental data last updated:September 12, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

 


Analyze GKOS on TradingView

VALUATION

P/E

-31.67

Market Cap ($M USD)

$6.07B

Forward P/E

22.32

PEG

0.09

PRICE TO SALES

11.01

PRICE TO BOOK

8.94

EV / EBITDA

-151.77

5-Year Average P/E

Free Cash Flow Yield

-0.30%

DCF Value

$-63.02

Graham Number

N/A

Price to FCF

-328.45

EV to FCF

-328.39

Earnings Yield

-3.16%

FCF Yield

-0.30%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$3.26

Next Year EPS Growth Estimate

$4.63

Next Year Revenue Growth Estimate

$1.55B

Return on Equity (ROE)

-26.46%

FREE CASH FLOW

Operating Margin

-15.58%

Debt-to-Equity

0.21

Piotroski F-Score

3

Altman Z-Score

16.22

Return on Invested Capital (ROIC)

-10.69%

Current Ratio

5.43

Quick Ratio

4.73

Net Debt to EBITDA

0.03

Interest Coverage

-18.69

Gross Profit margin

78.08%

FCF PER SHARE

$-0.32

REVENUE PER SHARE

$9.50

Analyze GKOS on TradingView

Gainseekers Quantitative Analysis

Summary

The market seems to be mispricing Glaukos Corporation, with its snapshot price trading significantly above its negative DCF value. The Forward P/E of 28.84 suggests optimism about future earnings, contrasting sharply with the current negative earnings yield. However, the Altman Z-score of 20.50 indicates robust financial health, suggesting low bankruptcy risk. Despite the negative ROIC and operating margin, the company appears to be positioned for growth, as evidenced by the substantial sales growth forecast.

AI Exposure / Tech Reliance

Operating within the Medical Devices industry, Glaukos is well-positioned to leverage AI advancements for precision in medical procedures and diagnostics. As healthcare increasingly integrates technology, the company can enhance its product offerings and operational efficiencies. This adaptability is crucial for maintaining a competitive edge in a rapidly evolving sector.

The Bull Case

For the value or GARP investor, Glaukos presents an intriguing opportunity. The Forward PEG ratio of 0.12 indicates potential undervaluation relative to its growth prospects. Despite a low Piotroski F-Score of 3, the company boasts a strong gross profit margin of 78.08%, suggesting significant pricing power. The high current ratio of 5.43 reflects solid liquidity, providing a cushion for strategic investments or downturns.

The Bear Case

Glaukos faces significant structural risks, particularly with its high valuation multiples. The Price/Book ratio of 11.55 and Price/Sales ratio of 14.22 suggest the stock is priced for perfection, leaving little room for error. Negative free cash flow and an EV to EBITDA of -196.08 highlight cash flow challenges, while the stock's proximity to its 52-week high indicates potential overextension. These factors could spell trouble if growth expectations aren't met.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$149.00

Institutional Ownership %

1-Year Beta

0.95

Insider Buying % (6 Mo)

Distance to 52-Week High

43.31%

Distance to 52-Week Low

29.21%

EARNINGS SURPRISE %

40.00%

50-DAY SMA

$122.16

200-DAY SMA

$105.72

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.